Skip to main content
Top

Cancer Chemotherapy and Pharmacology

Issue 6/2011

Content (31 Articles)

Open Access Original Article

A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

Paula M. Fracasso, Kerry J. Williams, Ronald C. Chen, Joel Picus, Cynthia X. Ma, Matthew J. Ellis, Benjamin R. Tan, Timothy J. Pluard, Douglas R. Adkins, Michael J. Naughton, Janet S. Rader, Matthew A. Arquette, James W. Fleshman, Allison N. Creekmore, Sherry A. Goodner, Lisa P. Wright, Zhanfang Guo, Christine E. Ryan, Yu Tao, Eliane M. Soares, Shi-rong Cai, Li Lin, Janet Dancey, Michelle A. Rudek, Howard L. McLeod, Helen Piwnica-Worms

Original Article

A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC

Athanasios G. Pallis, Vassilis Chandrinos, Georgia Pavlakou, Nikolaos Xenidis, Ioannis Varthalitis, Nikolaos Vardakis, Lambros Vamvakas, Emmanouel Kontopodis, Maria Rovithi, Vassilis Georgoulias

Original Article

Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer

Yen-Shen Lu, Dar-Ren Chen, Ling-Min Tseng, Dah-Cherng Yeh, Shou-Tung Chen, Chia-Ming Hsieh, Hwei-Chung Wang, Hsien-Tang Yeh, Sung-Hsin Kuo, Chiun-Sheng Huang

Original Article

A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy

Ken Kato, Makoto Tahara, Shuichi Hironaka, Kei Muro, Hiroya Takiuchi, Yasuo Hamamoto, Haruhiko Imamoto, Norihito Amano, Taku Seriu

Original Article

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

N. L. Steele, J. A. Plumb, L. Vidal, J. Tjørnelund, P. Knoblauch, P. Buhl-Jensen, R. Molife, R. Brown, J. S. de Bono, T. R. J. Evans

Original Article

A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan

Jen-Shi Chen, Yee Chao, Ruey-Kuen Hsieh, Ann-Lii Cheng, Po-Min Chen, Tzeon-Jye Chiou, Tsu-Yi Chao, Kun-Huei Yeh, Li-Tzong Chen, Jacqueline Whang-Peng

Original Article

Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model

Meredith K. Chuk, Diane E. Cole, Cynthia McCully, Natalia A. Loktionova, Anthony E. Pegg, Robert J. Parker, Gary Pauly, Brigitte C. Widemann, Frank M. Balis, Elizabeth Fox

Original Article

Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance

Murugan Kalimutho, Antonella Minutolo, Sandro Grelli, Amanda Formosa, Giulia Sancesario, Alessandra Valentini, Giorgio Federici, Sergio Bernardini

Original Article

Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant

S. Aubrey Stoch, Cynthia Gargano, Jack Valentine, Matthew P. Braun, M. Gail Murphy, Margaret Fedgchin, Anup Majumdar, Edward Pequignot, Keith M. Gottesdiener, Kevin J. Petty, Deborah Panebianco, Dennis Dean, Walter K. Kraft, Howard E. Greenberg

Original Article

Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis

Junshik Hong, Sae-Won Han, Hye Seon Ham, Tae-Yong Kim, In Sil Choi, Byung-Su Kim, Do-Youn Oh, Seock-Ah Im, Gyeong Hoon Kang, Yung-Jue Bang, Tae-You Kim

Original Article

Detection of doxorubicin hydrochloride accumulation in the rat brain after morphine treatment by mass spectrometry

Iacopo Sardi, Giancarlo la Marca, Maria Grazia Giovannini, Sabrina Malvagia, Renzo Guerrini, Lorenzo Genitori, Maura Massimino, Maurizio Aricò

Original Article

Preclinical pharmacokinetic, toxicological and biomarker evaluation of SR16157, a novel dual-acting steroid sulfatase inhibitor and selective estrogen receptor modulator

Linda Rausch, Carol Green, Karen Steinmetz, Sue LeValley, Paul Catz, Nurulain Zaveri, Karen Schweikart, Joseph Tomaszewski, Jon Mirsalis

Original Article

NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer

Johanna Hilli, Liisa Sailas, Sirkku Jyrkkiö, Seppo Pyrhönen, Kari Laine

Original Article

Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer

Chikara Kunisaki, Masazumi Takahashi, Hirochika Makino, Takashi Oshima, Shoichi Fujii, Ryo Takagawa, Jun Kimura, Takashi Kosaka, Hidetaka A. Ono, Hirotoshi Akiyama, Kunio Kameda, Fumihiko Kito, Satoshi Morita, Itaru Endo

Original Article

p53-dependent anticancer effects of leptomycin B on lung adenocarcinoma

Changxia Shao, Chuanwen Lu, Lixia Chen, Patrick P. Koty, Everardo Cobos, Weimin Gao

Original Article

Uncoupling protein downregulation in doxorubicin-induced heart failure improves mitochondrial coupling but increases reactive oxygen species generation

Heiko Bugger, Cinthia Guzman, Christoph Zechner, Monica Palmeri, Kerry S. Russell, Raymond R. Russell III

Open Access Original Article

Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin

Chi-Hui Tang, Christi Parham, Ellyn Shocron, Gerald McMahon, Neela Patel

Original Article

Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor

Edi Levi, Liyue Zhang, Amro Aboukameel, Sunny Rishi, Ramzi M. Mohammad, Lisa Polin, James S. Hatfield, Arun K. Rishi

Original Article

Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer

D. Takahari, T. Hamaguchi, K. Yoshimura, H. Katai, S. Ito, N. Fuse, T. Kinoshita, H. Yasui, M. Terashima, M. Goto, N. Tanigawa, K. Shirao, T. Sano, M. Sasako

Original Article

A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer

Masashi Kanai, Kenichi Yoshimura, Takehiko Tsumura, Masanori Asada, Chihiro Suzuki, Miyuki Niimi, Shigemi Matsumoto, Takafumi Nishimura, Takashi Nitta, Kentaro Yasuchika, Kojiro Taura, Yukiko Mori, Akihiko Hamada, Naoya Inoue, Shinsuke Tada, Kazuhiro Yanagihara, Shujiro Yazumi, Yukio Osaki, Tsutomu Chiba, Iwao Ikai, Masanori Fukushima, Shinji Uemoto, Etsuro Hatano

Original Article

Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer

Yoon-Koo Kang, Min-Hee Ryu, Changhoon Yoo, Heung-Moon Chang, Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim, Tae Won Kim

Original Article

Interleukin-1 receptor antagonist attenuates cyclophosphamide-induced mucositis in a murine model

Di Xiang, Yiping Guo, Jing Zhang, Jin Gao, Huili Lu, Shunying Zhu, Mingyuan Wu, Yan Yu, Wei Han

Clinical Trial Report

Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients

Carlo Buonerba, Piera Federico, Carmine D’Aniello, Pasquale Rescigno, Carla Cavaliere, Livio Puglia, Matteo Ferro, Vincenzo Altieri, Sisto Perdonà, Sabino De Placido, Giuseppe Di Lorenzo

Erratum

Erratum to: Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients

Carlo Buonerba, Piera Federico, Carmine D’Aniello, Pasquale Rescigno, Carla Cavaliere, Livio Puglia, Matteo Ferro, Vincenzo Altieri, Sisto Perdonà, Sabino De Placido, Giuseppe Di Lorenzo

Short Communication

Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy

Takeshi Masuda, Noboru Hattori, Akinobu Hamada, Hiroshi Iwamoto, Shinichiro Ohshimo, Masashi Kanehara, Nobuhisa Ishikawa, Kazunori Fujitaka, Yoshinori Haruta, Hiroshi Murai, Nobuoki Kohno

Short Communication

The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients

Sin-Chi Chew, Onkar Singh, Xiangai Chen, Rathi Devi Ramasamy, Tejal Kulkarni, Edmund J. D. Lee, Eng-Huat Tan, Wan-Teck Lim, Balram Chowbay

Letter to the Editor

Estimating the correct way of calculating the carboplatin dose

Jesús F. Sierra-Sánchez, Triana González-Carrascosa

Reply to the Letter

Prospectives and limitations by a novel algorithm

Karin Holweger, Hans-Peter Lipp

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine